ArticleBMC cancer2026
Extracellular vesicles derived from ovarian cancer cells promote tumor progression through m2 macrophage polarization and enhanced angiogenesis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer is one of the most lethal gynecologic malignancies worldwide, with tumor microenvironment playing a critical role in its progression. Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication within the tumor microenvironment, but their contribution to ovarian cancer progression through macrophage regulation remains poorly understood.
methodsEVs were isolated from ovarian cancer cell lines (SKOV3, HO8910, and ID8) by ultracentrifugation and characterized by transmission electron microscopy, nanoparticle tracking analysis, and western blot. The polarization of THP-1 macrophages and bone marrow-derived macrophages (BMDMs) was assessed after co-culture with cancer cells or treatment with cancer cell-derived EVs. Tube formation assays, cell proliferation, and VEGFR expression in human umbilical vein endothelial cells (HUVECs) were evaluated. In vivo, nude mice bearing SKOV3 tumors were treated with ovarian cancer-derived EVs, and tumor growth, macrophage infiltration, and angiogenesis were analyzed.
resultsOvarian cancer patients exhibited significantly increased M2-like monocytes proportions in both peripheral blood and tumor tissues compared to non-cancer controls (p < 0.05). CD31 expression was also elevated in ovarian cancer tissues and correlated with poor prognosis. In vitro, ovarian cancer cells promoted M2 polarization of macrophages (p < 0.001). EVs derived from ovarian cancer cells were successfully isolated, characterized, and shown to be internalized by macrophages. These cancer-derived EVs induced M2 polarization of macrophages (p < 0.0001) and enhanced the tube formation ability of HUVECs through upregulation of VEGFR expression. In the mouse model, ovarian cancer-derived EVs significantly promoted tumor growth (p < 0.0001), increased M2 macrophage infiltration, and enhanced CD31 expression compared to control groups.
conclusionsOur findings demonstrate that ovarian cancer-derived EVs promote tumor progression by inducing M2 macrophage polarization and enhancing angiogenesis. This study not only elucidates a novel mechanism by which ovarian cancer cells interact with the tumor microenvironment but also suggests that targeting cancer-derived EVs could be a promising therapeutic strategy for ovarian cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.